hGH fragment raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2026-06-17. Anything still debated is marked as such rather than presented as settled.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
AOD9604 is commonly supplied as a white to off-white lyophilized powder. The powder is typically stored at -20 °C or below, protected from light and moisture, because peptides can degrade through oxidation, hydrolysis, or aggregation. If it is reconstituted for laboratory use, an appropriate aqueous buffer or solvent is chosen, and the solution is kept cold and handled to avoid repeated freeze-thaw cycles. These practices support stability but do not imply suitability for human use.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
Proposed mechanisms for AOD-9604 focus on fat cells. Laboratory studies suggest the peptide can increase lipolysis, the breakdown of stored fat, and reduce lipogenesis, the formation of new fat. Unlike full human growth hormone, it does not appear to stimulate substantial IGF-1 production in the studies reported so far. Some evidence points to beta-adrenergic signaling, but the precise receptor targets and downstream pathways remain unresolved. The fragment is not thought to act through the classical growth hormone receptor.
Niemann-Pick disease type C1 protein, which participates in the intracellular movement of cholesterol Patched, the receptor for Hedgehog, a protein that contains covalently bound cholesterol Oxysterols regulate cholesterol homeostasis through liver X receptor (LXR) and sterol regulatory element-binding protein (SREBP) mediated signaling pathway. This protein binds to the sterol-sensing domains of SREBP cleavage-activating protein (SCAP) and HMG CoA reductase, and is essential for the sterol-mediated trafficking of the two proteins. Alternatively spliced transcript variants encoding distinct isoforms have been observed.
When Norse Vikings from Scandinavia arrived in the then-province of Neustria and settled the land that became known as Normandy, they originally spoke Old Norse, a North Germanic language. Over time, they came to live among the local Gallo-Romance-speaking population, with the two communities converging to the point that the original Norsemen largely assimilated and adopted the local dialect of Old French while contributing some elements from the Old Norse language. This Norse-influenced dialect which then arose was known as Old Norman, and it is the ancestor of both the modern Norman language still spoken today in the Channel Islands and parts of mainland Normandy, as well as the historical Anglo-Norman language in England. Old Norman was also an important language of the Principality of Antioch during Crusader rule in the Levant. Old Norman and Anglo-Norman literature was quite extensive during the Middle Ages, with records existing from notable Norman poets such as Wace, who was born on the island of Jersey and raised in mainland Normandy.
=== Expansion and loss === Typical GSH-Px and superoxide dismutase enzymes requrire trace elements including selenium, vanadium, magnesium, copper, and zinc. These elements tend to be abundant in marine environments but can be lacking in some terrestrial mineral-deficient areas. Organisms have accordingly expanded or reduced their seleno-proteomes (arsenal of selenoproteins) to adapt to the situation. As land plants adapted to the terrestrial environment from about 500 million years ago, they too faced the problem of a lack of these elements. Accordingly, most land plants do not produce selenoproteins. For their anti-oxidation needs, they slowly optimized the production of "new" endogenous antioxidants such as ascorbic acid (Vitamin C), polyphenols (including flavonoids), tocopherols, etc. A few of these appeared more recently, in the last 50–200 million years, in fruits and flowers of angiosperm plants. In fact, the angiosperms (the dominant type of plant today) and most of their antioxidant pigments evolved during the late Jurassic period. The vertebrates of 500 million years ago were marine fishes. They opted to expand their seleno-proteomes, most notably evolving a thyroid gland with high concentration of selenium and iodine and associated systems. A group of them, the tetrapoda, later adapted to life on land but retained many of the ancestral selenoproteins.
== Discovery and development == Tralokinumab was discovered by Cambridge Antibody Technology scientists using protein optimization based on Ribosome Display. They used the extensive data sets from ribosome display to patent protect CAT-354 in a world-first of sequence-activity-relationship claims. In 2004, clinical development of CAT-354 was initiated with this first study completing in 2005. On 21 July 2011, MedImmune LLC initiated a Phase IIb, randomized, double-blind study to evaluate the efficacy of tralokinumab in adults with asthma. In 2016, MedImmune and AstraZeneca started developing tralokinumab for asthma (Phase III) and atopic dermatitis (Phase IIb) while clinical development for moderate-to-severe ulcerative colitis and idiopathic pulmonary fibrosis (IPF) have been discontinued. In July of that year AstraZeneca licensed tralokinumab to Leo Pharma for skin diseases. A phase IIb study of tralokinumab found that treatment was associated with early and sustained improvements in atopic dermatitis symptoms and tralokinumab had an acceptable safety and tolerability profile, thereby providing evidence for targeting IL-13 in patients with atopic dermatitis. In June 2017, Leo Pharma started phase III clinical trials with tralokinumab in atopic dermatitis.
CH stations were designed to operate at 20–50 MHz, the "boundary area" between high frequency and VHF bands at 30 MHz, although typical operations were at 20–30 MHz (the upper end of the HF band), or about a 12 m wavelength (25 MHz). The detection range was typically 120 mi (190 km; 100 nmi), but could be better. The main limitation in use was that Chain Home was a fixed system, non-rotational, which meant it could not see beyond its sixty-degree transmission arc or behind it once the targets had flown overhead, and so raid plotting over land was down to ground observers, principally the Observer Corps (from April 1941 known as the Royal Observer Corps). Ground-based observation was acceptable during the day but useless at night and in conditions of reduced visibility. This problem was lessened on introduction of more advanced surveillance radars with 360-degree tracking and height-finding capability and, more importantly, aircraft fitted with Airborne Intercept radar (AI), which had been developed in parallel with Chain Home from 1936 onwards. This new equipment began to appear in late 1940 fitted to Bristol Blenheim, Bristol Beaufighter and Boulton Paul Defiant aircraft. Even as the CH system was being deployed, a wide variety of experiments with newer designs was being carried out. By 1941 the Type 7 Ground Control Intercept Radar (GCI) on a wavelength of 1.5 m was entering production, and reached widespread service in 1942.
Sources: en.wikipedia.org
The problem is, of course, that they can't afford to fail. The rules of the game are that you don't take a chance, because if you fail, then probably your whole program gets wiped out. Dyson still hoped for cheap space travel, but was resigned to waiting for private entrepreneurs to develop something new and inexpensive.
=== Carbamylated proteins === Within nature carbon dioxide can bind with neutral amine groups to form a carbamate. This post-translational modification is known as carbamylation, and is known to occur on several important proteins. The N-terminal amino groups of valine residues in the α- and β-chains of deoxyhemoglobin exist as carbamates. They help to stabilise the protein when it becomes deoxyhemoglobin, and increases the likelihood of the release of remaining oxygen molecules bound to the protein. This stabilizing effect should not be confused with the Bohr effect (an indirect effect caused by carbon dioxide). The ε-amino groups of the lysine residues in urease and phosphotriesterase also feature carbamate.
=== Celeste Pacquet === Celeste Pacquet (Katrine De Candole) is a private wealth manager at Pierpoint. Yasmin meets her at a party hosted by her family friend Maxim Alonso, and Celeste plays along with Yasmin's assumption that she is a sex worker before eventually revealing her actual job. Yasmin, growing disgruntled with the FX desk, becomes increasingly drawn to working for PWM, in part due to her escalating flirtation with Celeste. Yasmin and Celeste eventually have sex, but Celeste reveals she is already in an open marriage with her wife and resents the power imbalance in their relationship, making Yasmin realize their affair is not as significant as she imagined. Yasmin brings in her father, Charles Hanani, as a PWM client, but soon regrets it after learning about his various affairs and subsequent NDA settlements, realizing he is a sexual predator. Celeste refuses to cut ties with Charles despite knowing about his inappropriate behavior firsthand, telling Yasmin that it is "better to work within a system and succeed than to wish for it to change and be left behind." A disillusioned Yasmin cuts ties with Celeste shortly thereafter.
The posters featured Gilroy's distinctive artwork and more often than not featured animals such as a kangaroo, ostrich, seal, lion and notably a toucan, which has become as much a symbol of Guinness as the harp. (An advertisement from the 1940s ran with the following jingle: "Toucans in their nests agree/Guinness is good for you/Try some today and see/What one or toucan do.") Dorothy L. Sayers and R. A. Bevan copywriters at Benson's also worked on the campaign; a biography of Sayers notes that she created a sketch of the toucan and wrote several of the adverts in question. Guinness advertising paraphernalia, notably the pastiche booklets illustrated by Ronald Ferns, attract high prices on the collectable market.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
Lyophilized AOD9604 is generally kept at -20 °C or colder, desiccated, and protected from light. Reconstituted solutions are usually refrigerated and handled to minimize repeated freeze-thaw cycles. These are general laboratory handling practices, not instructions for human use.